Cargando…

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes

BACKGROUND: Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs with respect to incident type 2 diabetes in individuals with impaired glucose tol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coleman, Ruth L., Scott, Charles A. B., Lang, Zhihui, Bethel, M. Angelyn, Tuomilehto, Jaakko, Holman, Rury R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798440/ https://www.ncbi.nlm.nih.gov/pubmed/31623625 http://dx.doi.org/10.1186/s12933-019-0933-y

Ejemplares similares

Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial
por: Kraus, William E, et al.
Publicado: (2018)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
por: Bethel, M. Angelyn, et al.
Publicado: (2023)

Evaluation of a Self-Administered Oral Glucose Tolerance Test
por: Bethel, M. Angelyn, et al.
Publicado: (2013)

Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study
por: Xu, Shishi, et al.
Publicado: (2022)

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
por: Nakamura, Kazufumi, et al.
Publicado: (2014)

Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study
por: Chan, Cheng-Wei, et al.
Publicado: (2018)

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
por: Nauck, Michael A., et al.
Publicado: (2019)

Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes
por: van de Laar, Floris Alexander
Publicado: (2008)

Cinnamoyl Sucrose Esters as Alpha Glucosidase Inhibitors for the Treatment of Diabetes
por: Devaraj, Surabhi, et al.
Publicado: (2021)

Intestinal Production of Alpha-Glucosidase Inhibitor by Bacillus coagulans Spores
por: Kim, Hee-Woong, et al.
Publicado: (2023)

Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis
por: Zhang, Longhao, et al.
Publicado: (2016)

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
por: Clegg, Lindsay E., et al.
Publicado: (2019)

Peptide modulators of alpha-glucosidase
por: Roskar, Irena, et al.
Publicado: (2015)

Screening of Aqueous Extract of Persea americana Seeds for Alpha-Glucosidase Inhibitors
por: Lawal, Tajudeen Afolayan
Publicado: (2022)

Pneumatosis Intestinalis Induced by Alpha-Glucosidase Inhibitors in Patients with Diabetes Mellitus
por: McKinley, Blake J., et al.
Publicado: (2022)

Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis
por: Zhao, Yiming, et al.
Publicado: (2017)

Meta‐analysis and critical review on the efficacy and safety of alpha‐glucosidase inhibitors in Asian and non‐Asian populations
por: Gao, Xueying, et al.
Publicado: (2017)

HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
por: Bethel, M. Angelyn, et al.
Publicado: (2021)

Progression of glucose‐lowering diabetes therapy in TECOS
por: Bethel, M. Angelyn, et al.
Publicado: (2018)

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
por: Idzerda, Nienke M. A., et al.
Publicado: (2020)

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study
por: Cox, David A., et al.
Publicado: (2022)

Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis
por: Zhang, Lingshu, et al.
Publicado: (2020)

Alpha-glucosidase inhibitors from Nervilia concolor, Tecoma stans, and Bouea macrophylla
por: Ha, Kim-Ngoc, et al.
Publicado: (2022)

Experimental and Computational Analysis of Newly Synthesized Benzotriazinone Sulfonamides as Alpha-Glucosidase Inhibitors
por: Khalid, Zunera, et al.
Publicado: (2022)

Obesity attenuates gender differences in cardiovascular mortality
por: Song, Xin, et al.
Publicado: (2014)

Four‐year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation
por: Miao, Benjamin, et al.
Publicado: (2020)

Association of ADIPOR2 gene variants with cardiovascular disease and type 2 diabetes risk in individuals with impaired glucose tolerance: the Finnish Diabetes Prevention Study
por: Siitonen, Niina, et al.
Publicado: (2011)

Comparison of oral glucose tolerance test and HbA1c in detection of disorders of glucose metabolism in patients with acute stroke
por: Matz, Karl, et al.
Publicado: (2020)

Historical HbA(1c) Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88
por: Lind, Marcus, et al.
Publicado: (2021)

A Combined Experimental and Computational Study of Novel Benzotriazinone Carboxamides as Alpha-Glucosidase Inhibitors
por: Khalid, Zunera, et al.
Publicado: (2023)

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
por: Ferrannini, Giulia, et al.
Publicado: (2021)

Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort
por: Simmons, Rebecca K., et al.
Publicado: (2009)

Triglyceride–glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies
por: Ding, Xiaobo, et al.
Publicado: (2021)

Association of Trajectory of Cardiovascular Health Score and Incident Cardiovascular Disease
por: Wu, Shouling, et al.
Publicado: (2019)

Comparisons of the Efficacy of Alpha Glucosidase Inhibitors on Type 2 Diabetes Patients between Asian and Caucasian
por: Cai, Xiaoling, et al.
Publicado: (2013)

Recent Updates on Phytoconstituent Alpha-Glucosidase Inhibitors: An Approach towards the Treatment of Type Two Diabetes
por: Kashtoh, Hamdy, et al.
Publicado: (2022)

Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis
por: Yen, Fu-Shun, et al.
Publicado: (2022)

Health selection into neighborhoods among patients enrolled in a clinical trial
por: Arcaya, Mariana C., et al.
Publicado: (2017)

The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender
por: Hyvärinen, Marjukka, et al.
Publicado: (2009)

Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis
por: Mincu, Raluca I., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rtuk35h0brecr7767b1na01n20